Ibogaine deaths: what is known

Deaths following ibogaine use are documented in the peer-reviewed literature, and the physiological route by which they occur is reasonably well understood. This entry sets out what the record contains. It is the least comfortable material on this site and also the most important, because the decisions people make about ibogaine depend more on this than on any efficacy figure.

Two things need separating from the outset. The first is the mechanism: ibogaine affects the electrical behaviour of heart muscle in a specific, measurable way, and that effect is the plausible cause of the deaths that have been reported. The second is the frequency, which nobody can state reliably, for reasons set out below. Claims of a precise fatality rate, in either direction, should be treated with suspicion.

The position in brief

Ibogaine prolongs the QT interval on an electrocardiogram, a measure of how long the heart's electrical cycle takes to reset. Prolongation of that interval is associated with a particular form of dangerous arrhythmia, and a 2019 pharmacology review states directly that QT prolongation after ibogaine has been associated with cases of sudden death [1]. A 2026 review of human research records serious adverse events in the literature, cardiotoxicity from QT prolongation in particular [9].

Fatalities are documented mainly in medically unsupervised settings, and a 2026 review of emerging treatments notes exactly that, suggesting that prescreening and cardiac monitoring may reduce the risk [8]. The word in that sentence doing the work is reduce. Screening and monitoring change the odds and the response time. They do not remove the drug's effect on the heart.

The physiological route

The heart's electrical reset depends partly on potassium moving out of heart muscle cells through a channel known as hERG. Laboratory work on human hERG channels expressed in cultured cells found that ibogaine reduces current through them at concentrations comparable to those reached in treatment, which provides a mechanism for arrhythmia [2]. A review by the same group reports the concentration producing half-maximal block at around 4 micromolar [3].

When that channel is partly blocked, repolarisation takes longer, the QT interval lengthens, and the heart becomes more vulnerable to a disorganised rhythm called torsades de pointes, which can progress to cardiac arrest. This is not peculiar to ibogaine. A long list of medicines carry QT warnings for the same reason, and clinical practice around them is built on measuring the interval before and during exposure.

One feature makes ibogaine harder to manage than most. The review of its cardiac pharmacology notes that QT prolongation outlasts the presence of ibogaine in the blood [3]. The risk window therefore does not close when the acute psychoactive effects subside, which is why monitoring schedules that end with the experience are inadequate.

How large the cardiac effect is

The clearest numbers come from a Dutch study of 14 adults with opioid use disorder, conducted in a university psychiatry department with careful exclusions. Participants with a QT interval already above 450 milliseconds in men or 470 in women were excluded, as were those with potassium outside a normal range, severe liver or kidney dysfunction, or any QT-prolonging or CYP2D6-affecting medication. Magnesium was given if the interval passed 500 milliseconds [4].

Even with that screening, maximum QT prolongation averaged 95 milliseconds, with a range from 29 to 146. Seven of the 14 passed 500 milliseconds. In 6 of 14 an interval above 450 milliseconds persisted beyond 24 hours. No torsades de pointes occurred. All 14 developed severe transient ataxia and could not walk unaided [4].

Those figures deserve to be read slowly. Half of a carefully screened group crossed a threshold that would trigger intervention in any hospital. The study recorded no arrhythmia, which is a reassuring outcome in 14 people and says nothing about what happens in the hundredth or the thousandth. A 191-person inpatient series in St Kitts, which screened with physical examination, safety labs and a 12-lead electrocardiogram and ran telemetry from an hour before dosing to 24 hours after, reported no serious adverse events and no deaths [7]. Those two datasets together are the best available picture of what supervision achieves, and they total around 200 people.

A death inside a published study

The most instructive single case is recorded in a New Zealand observational study, because it happened within a research protocol and was investigated formally. Fifteen people enrolled; one died during treatment and one was disqualified, leaving 14 analysed. The participants were adults aged 28 to 47, 71 percent of them on methadone maintenance, treated by two legal providers with staggered oral doses totalling 25 to 55 milligrams per kilogram over 24 to 96 hours [5].

The coroner found no significant cardiac pathology in the person who died, and judged the death very likely related to ibogaine ingestion and most probably to a cardiac arrhythmia. The provider was found to have breached its duty of care [5], a finding examined in a separate decision by New Zealand's Health and Disability Commissioner [10].

Two details carry weight. The absence of significant cardiac pathology means the person had no identifiable pre-existing heart disease that screening would have flagged. And the regimen was staggered over up to four days at cumulative doses well above the single doses used in the inpatient series, which is a different exposure pattern altogether. The case is a demonstration that a person without detectable cardiac disease can die after ibogaine in a legal, provider-administered setting.

Why the same dose is not the same exposure

A substantial part of the risk comes from variation between people in how fast they clear the drug. Ibogaine is converted to noribogaine primarily by the liver enzyme CYP2D6, whose activity is genetically variable. In the Dutch cohort, CYP2D6 genotype drove a more than tenfold spread in ibogaine clearance, and the study found that QT prolongation and ataxia tracked ibogaine levels rather than noribogaine levels [6].

The consequence is direct. Two people given an identical dose per kilogram can reach very different blood concentrations, and the one who clears the drug slowly is exposed to the cardiac effect for longer and more intensely. The cardiac review notes that CYP2D6 function is absent in roughly 5 to 10 percent of people of European ancestry [3], so slow metabolisers are not rare.

Medication makes this worse. The same review notes that methadone inhibits CYP2D6 and is likely to impair ibogaine metabolism [3]. Since a large share of people seeking ibogaine for opioid dependence are on methadone, the population most likely to seek treatment overlaps with the population most likely to clear it slowly. That interaction is one of the clearest identifiable risk factors in the whole picture.

Why unsupervised use carries the most risk

In an unsupervised setting none of the protective steps is available. There is no electrocardiogram to establish a baseline interval, so a person already above the threshold cannot be identified. There is no blood test, so low potassium or magnesium, which independently increase arrhythmia risk, goes undetected. There is no medication review, so a QT-prolonging drug or a CYP2D6 inhibitor may be in the system. And there is no monitoring, so an arrhythmia developing over hours is not seen and not treated.

Added to that is the problem of the material itself. Purity and alkaloid content vary between preparations, so a stated dose may not correspond to the amount of ibogaine actually taken. A person cannot calculate their exposure from a label they cannot verify.

What supervision does and does not change

Supervision changes four things. It excludes people with detectable cardiac disease, electrolyte abnormality or interacting medication. It establishes a baseline measurement so change can be tracked. It places the person where an arrhythmia can be recognised quickly. And it puts equipment and trained staff within reach if one occurs, which is the difference between a treatable event and a fatal one.

What supervision does not do is remove the hERG effect, make the interval stop lengthening, or predict which individual will clear the drug slowly unless genotyping is done in advance. Nor does it extend protection beyond the period monitored, which matters given that prolongation outlasts the drug [3]. Anyone presenting screening as a promise of safety is misdescribing what it is.

There is one further limit worth naming. The two supervised datasets that reported no deaths were both conducted by teams who published their methods, screened to explicit criteria and monitored to a defined schedule [4] [7]. A setting that describes itself as medically supervised is not necessarily operating to that standard, and the phrase carries no accreditation behind it. The practical questions are concrete: what screening is performed, whether an electrocardiogram and electrolytes are taken before dosing, what monitoring runs during and for how many hours after, what cardiac equipment is on site, and who present is qualified to use it.

Why nobody can give a reliable rate

A credible fatality rate needs a numerator and a denominator. The numerator is incomplete: deaths are captured through case reports, coroners' findings and media attention, and an unknown number of deaths in informal settings never reach any of those. The denominator is worse, because nobody knows how many people take ibogaine, where, at what dose, or with what preparation. Treatment largely happens outside systems that record it.

Numbers circulate anyway. They are derived from assumptions about both figures, and the uncertainty in those assumptions is wide enough that the resulting estimate carries little information. The defensible statement is qualitative: deaths have occurred, the route by which they occur is understood, the risk is concentrated in unsupervised use, and the magnitude of the cardiac effect even under careful supervision is substantial [4].

Frequently asked questions

That uncertainty cuts in a specific direction. It means the absence of a high published death count is not evidence that the risk is low, because the counting system that would detect those deaths does not exist. It also means a person cannot reason from the fact that many others appear to have come through treatment, since no one knows how many did not. The physiology is the firmer ground: a measurable, documented effect on cardiac repolarisation, varying widely between individuals, lasting longer than the drug itself.

What actually causes death after ibogaine?

The documented route is cardiac. Ibogaine blocks the hERG potassium channel in heart muscle at relevant concentrations [2], lengthening the QT interval, which is associated with sudden death after ibogaine [1]. In the New Zealand case the coroner judged a cardiac arrhythmia the most probable mechanism [5].

Does a normal heart mean it is safe?

No. The person who died in the New Zealand study was found at autopsy to have no significant cardiac pathology [5]. Screening removes identifiable risk factors; it does not identify everyone at risk.

How long does the cardiac risk last?

Longer than the experience. QT prolongation outlasts the presence of ibogaine in blood [3], and in a screened cohort an interval above 450 milliseconds persisted beyond 24 hours in 6 of 14 patients [4].

Is methadone a specific concern?

Yes. Methadone inhibits CYP2D6, the enzyme that clears ibogaine, and is likely to impair its metabolism [3], while CYP2D6 genotype alone drives a more than tenfold spread in clearance [6].

How many people have died?

No reliable count exists, because neither the number of deaths nor the number of people treated is systematically recorded. Reviews state that fatalities are documented, mainly in medically unsupervised settings [8] [9], without a dependable rate.